PriceTargets.com logo

KALA BIO - KALA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 153.38%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.92 As of 12/20/2024 06:16 PM ET
▼ -0.08 (-1.33%)

This chart shows the closing price for KALA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New KALA BIO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KALA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KALA

Analyst Price Target is $15.00
▲ +153.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for KALA BIO in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 153.38% upside from the last price of $5.92.

This chart shows the closing price for KALA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in KALA BIO. This rating has held steady since March 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/19/2024OppenheimerReiterated RatingOutperform ➝ Outperform$15.00 ➝ $15.00
5/17/2024HC WainwrightLower TargetBuy ➝ Buy$21.00 ➝ $18.00
4/2/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $21.00
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$15.00
11/17/2023HC WainwrightLower TargetBuy ➝ Buy$24.00 ➝ $22.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$24.00
5/10/2023HC WainwrightBoost Target$22.00 ➝ $24.00
4/12/2023HC WainwrightBoost TargetBuy$20.00 ➝ $22.00
3/27/2023HC WainwrightReiterated RatingBuy$20.00
3/6/2023HC WainwrightBoost TargetBuy$12.00 ➝ $20.00
11/9/2022WedbushBoost Target$3.00 ➝ $47.00
8/15/2022HC WainwrightLower TargetBuy$100.00 ➝ $62.50
5/24/2022HC WainwrightLower TargetBuy$125.00 ➝ $100.00
5/17/2022WedbushLower TargetNA$150.00 ➝ $75.00
5/17/2022HC WainwrightLower TargetBuy$150.00 ➝ $125.00
3/30/2022Northland SecuritiesLower TargetOutperform$150.00 ➝ $100.00
3/30/2022HC WainwrightLower TargetBuy$225.00 ➝ $150.00
3/30/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$37.50
12/15/2021WedbushReiterated RatingOutperform
11/16/2021Northland SecuritiesLower TargetOutperform$300.00 ➝ $150.00
11/16/2021HC WainwrightLower TargetBuy$275.00 ➝ $225.00
10/21/2021HC WainwrightReiterated RatingBuy$275.00
8/6/2021HC WainwrightLower TargetBuy$350.00 ➝ $275.00
8/6/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
6/4/2021HC WainwrightReiterated RatingBuy$350.00
5/12/2021HC WainwrightLower TargetBuy$400.00 ➝ $350.00
5/6/2021HC WainwrightReiterated RatingBuy$400.00 ➝ $350.00
2/17/2021HC WainwrightReiterated RatingBuy$425.00
11/30/2020Northland SecuritiesReiterated RatingBuy$425.00
10/28/2020WedbushBoost TargetOutperform$975.00 ➝ $1,175.00
10/5/2020WedbushReiterated RatingBuy$975.00
9/14/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$525.00 ➝ $250.00
8/18/2020WedbushReiterated RatingBuy$975.00
8/7/2020Northland SecuritiesReiterated RatingBuy$425.00
8/4/2020WedbushReiterated RatingBuy$975.00
7/23/2020Northland SecuritiesInitiated CoverageOutperform$425.00
6/14/2020WedbushReiterated RatingBuy$975.00
6/2/2020WedbushReiterated RatingBuy$975.00
5/29/2020OppenheimerInitiated CoverageOutperform$400.00 ➝ $525.00
5/27/2020JPMorgan Chase & Co.Boost TargetOverweight$350.00 ➝ $475.00
5/27/2020HC WainwrightReiterated RatingBuy$350.00 ➝ $425.00
5/11/2020WedbushReiterated RatingBuy$875.00
5/8/2020HC WainwrightBoost TargetBuy$325.00 ➝ $350.00
5/4/2020WedbushReiterated RatingBuy$850.00
4/22/2020WedbushReiterated RatingBuy$850.00
4/13/2020HC WainwrightReiterated RatingBuy$325.00
3/29/2020WedbushReiterated RatingBuy$850.00
3/18/2020HC WainwrightBoost TargetBuy$250.00 ➝ $325.00
3/17/2020WedbushReiterated RatingBuy$850.00
3/10/2020OppenheimerBoost TargetOutperform$325.00 ➝ $400.00
3/10/2020WedbushBoost TargetOutperform$1,275.00 ➝ $1,300.00
3/9/2020Bank of AmericaUpgradeNeutral ➝ Buy$375.00
3/9/2020WedbushReiterated RatingBuy$1,275.00
2/12/2020WedbushReiterated RatingBuy$1,275.00
1/21/2020HC WainwrightReiterated RatingBuy$250.00
12/23/2019WedbushReiterated RatingBuy$1,275.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More

Today's Range

Now: $5.92
Low: $5.75
High: $6.04

50 Day Range

MA: $6.44
Low: $5.11
High: $7.63

52 Week Range

Now: $5.92
Low: $4.21
High: $9.25

Volume

12,938 shs

Average Volume

78,538 shs

Market Capitalization

$27.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of KALA BIO?

The following sell-side analysts have issued stock ratings on KALA BIO in the last year: HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for KALA.

What is the current price target for KALA BIO?

0 Wall Street analysts have set twelve-month price targets for KALA BIO in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 153.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting KALA will reach $15.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $15.00 for KALA BIO in the next year.
View the latest price targets for KALA.

What is the current consensus analyst rating for KALA BIO?

KALA BIO currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KALA will outperform the market and that investors should add to their positions of KALA BIO.
View the latest ratings for KALA.

What other companies compete with KALA BIO?

Other companies that are similar to KALA BIO include Maxpro Capital Acquisition, INmune Bio, Adverum Biotechnologies, Cardiol Therapeutics and Journey Medical. Learn More about companies similar to KALA BIO.

How do I contact KALA BIO's investor relations team?

KALA BIO's physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company's listed phone number is (781) 996-5252 and its investor relations email address is [email protected]. The official website for KALA BIO is www.kalarx.com. Learn More about contacing KALA BIO investor relations.